CRISPR Therapeutics reported fourth-quarter and full-year 2025 results, spotlighting commercial traction for CASGEVY and a pipeline tilting from ex vivo cell therapy toward in vivo editing and RNA medicines. CASGEVY generated $54 million in Q4 and $116 million for 2025, with 64 patients infused during the year and 147 initiating first cell collection. Regulatory and reimbursement access widened across the U.S., Europe, and the Gulf, with roughly 90% of eligible U.S. patients covered. Pediatric submissions for CASGEVY in ages 5–11 are planned in the first half of 2026 with expedited U.S. review. The company closed 2025 with $2.0 billion in cash and advanced multiple programs, including an ANGPTL3 editor (CTX310) in Phase 1b, a next-generation Lp(a) editor (CTX321) entering IND/CTA-enabling studies, a first Syntase platform candidate for AATD (CTX460) slated for mid-2026, an AGT editor for refractory hypertension (CTX340) expected to enter the clinic in the first half of 2026, and an FXI siRNA (CTX611) in Phase 2 under its Sirius Therapeutics collaboration. Allogeneic CD19 CAR-T zugo-cel progressed across autoimmune indications and B-cell malignancies.
The strategic question is whether CRISPR Therapeutics can convert early, high-science wins into a durable, multi-franchise business. CASGEVY’s momentum validates the first generation of CRISPR-enabled autologous therapies, yet the operational intensity of myeloablation, specialized centers, and stepwise patient initiation remains a growth governor. The company’s answer appears to be diversification: combine near-term revenue share from CASGEVY with less infrastructure-heavy in vivo liver editing and a chronic, payer-familiar siRNA franchise, while keeping an option on an off-the-shelf autoimmune CAR-T category that could reset treatment paradigms.
This matters now for three constituencies. Patients stand to benefit from faster access and potential earlier intervention as pediatric filings advance; the pediatric label could accelerate referrals and reshape lifetime disease management in sickle cell disease and beta thalassemia. Payers face the next phase of budget impact as patient initiations roughly tripled versus 2024 and ex-U.S. reimbursement spreads; evidence demands will intensify around long-term durability, fertility, and health system offsets, particularly in younger cohorts. Health care providers and authorized centers must scale capacity, streamline conditioning logistics, and refine selection criteria to sustain throughput and manage post-procedure care, while Medical Affairs teams seed real-world evidence to smooth payer deliberations and inform guideline updates.
The pipeline signals where gene editing is heading: from rare hematology into cardiometabolic disease and thrombosis. ANGPTL3 and Lp(a) offer genetically validated targets with large prevalent populations, where one-time editing could challenge chronic therapy economics, while the FXI siRNA program positions the company inside an increasingly competitive low-bleed anticoagulation race with an administration schedule designed for adherence. Autoimmune CAR-T continues to attract outsized attention as case experience accumulates; an allogeneic entrant with proprietary edits and in-house GMP could offer speed and scale advantages if safety and durability hold. The Sirius alliance underscores a broader industry pivot toward hybrid modality portfolios that balance one-time curatives with recurring revenue therapies, hedging scientific and reimbursement risk.
The next 12–18 months will test execution more than science. CASGEVY’s pediatric review, FXI Phase 2 progress, initial clinical entries for AATD and refractory hypertension, and clarity on zugo-cel’s autoimmune data will determine how quickly CRISPR Therapeutics can rebalance from a single commercial royalty stream to multiple value drivers. The open question for commercial and medical leaders is whether this cross-modality strategy can compress adoption curves and payer friction faster than capacity and evidence constraints push back, and, if in vivo editing meets its durability promise, how soon chronic care markets will be willing to trade decades of drug spend for a single definitive intervention.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
